1)  hypoxia inducible factor-1
去铁铵
2)  deferiprone
去铁酮
1.
Effect of deferiprone on contents of Ca,Zn,Mg in brain,liver,kidney and bone tissue of aluminum-exposed mice;
去铁酮对铝染毒小鼠脑、肝、肾、骨组织中钙、锌、镁含量的影响
2.
Pharmacokinetics and bioequivalence of deferiprone extended-release tablets in Beagle dogs;
去铁酮缓释片在犬体内的药动学及生物等效性
3.
Objective: To evaluate the safety and efficacy of combining deferiprone(DFP)and deferoxamine(DFO)in iron chelation therapy in patients with thalassemia.
目的:探讨去铁酮(DFP)和去铁胺(DFO)联合用药对重症地中海贫血螯合治疗的安全性和有效性。
3)  desferrioxamine
去铁胺
1.
The Antiproliferative Effect of Desferrioxamine on K562 Cell and Its Influence on Cell Cycle;
去铁胺抗K562细胞的增殖作用及对细胞周期的影响
2.
Methods:K562 cells treated with desferrioxamine (DFO) at different concentration (25 μmol/L and 50 μmol/L) were collected at different time point(16 h,24 h,32 h,48 h,72 h) and labelled with Annexin V/PI.
方法实验组以不同浓度(25μmol/L、50μmol/L)的去铁胺处理K562细胞,25μmol/L去铁胺加等浓度的三氯化铁作对抗组,设空白对照组,分别收集不同时间点(16h、24h、32h、48h、72h)的细胞,用磷脂结合蛋白V/碘化丙啶(AnnexinV/PI)进行双标记,荧光显微镜观察凋亡细胞的形态变化。
3.
The iron deprivation was induced by adding desferrioxamine (DFO) 10-100 μmol/L for 0-48 hours.
为了研究细胞可变铁池(labileironpool,LIP)的检测方法,用不同浓度的去铁胺(DFO)与K562及HL-60细胞共同培养0、6、12、24、48小时,用钙荧光素(caicein)负荷K562及HL-60细胞,荧光分辨仪检测细胞荧光量;用快速铁螯合剂螯合铁,使恢复荧光,然后计算2次荧光差值。
4)  Deferoxamine
去铁胺
1.
Deferoxamine protects against amikacin ototoxicity and ist mechanism;
甲磺酸去铁胺抗丁胺卡那霉素耳毒性作用及机理研究
2.
Objective To observe the change of mitochondrion membrane potential(ΔΨm) in apoptosis induced by an iron chelator(deferoxamine,DFO),and to explore the mechanism of this apoptosis in human leukemia-60(HL-60) cells.
方法HL-60细胞分别与10、50、100μmol/L去铁胺(DFO)和10、100μmol/L三氯化铁(FeCl3)共培养,分别造成细胞内铁剥夺和富铁状态,噻唑蓝(MTT)法检测不同铁状态下细胞活力变化;相差显微镜观察凋亡细胞的形态学改变,流式细胞仪(FCM)检测细胞凋亡率及ΔΨm变化;原位杂交法检测凋亡基因Bax转录水平。
3.
This study was purposed to observe the changes of caspase-3 activity during apoptosis of HL-60 cells induced by an iron chelator, DFO (deferoxamine), and to explore the mechanism underlying apoptosis in HL-60 cells.
为了研究铁螯合剂—去铁胺(deferoxamine,DFO)诱导人白血病细胞株HL-60凋亡时半胱天冬酶-3(caspase-3)活性的变化并探讨DFO诱导凋亡的可能机制。
5)  DFO
去铁胺
1.
Methods HL-60 cells were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum which was treated with ferric chloride(FeCl3) or deferoxamine(DFO).
方法将FeCl3或去铁胺(Desferrioxamine,DFO)加入含有体积分数10%胎牛血清的RPMI-1640培养液中,使HL-60细胞处于缺铁或富铁的不同状态下培养。
2.
To observe the effect of DFO on iron metabolism in primary cultured rats cardiac myocytes.
观察去铁胺(DFO)对原代培养的心肌细胞铁代谢的影响,探讨DFO对心肌细胞铁代谢的影响机制。
6)  deferasirox
去铁斯若
1.
Pharmacology and clinical evaluation of deferasirox;
铁螯合剂去铁斯若的药理与临床评价
参考词条
补充资料：EDTA铁铵
CAS：21265-50-9
分子式：C10H20FeN3O10
分子质量：398.12

中文名称：EDTA铁铵；乙二胺四乙酸铁铵盐；EDTA铁铵盐
英文名称：[[N,N'-1,2-ethanediylbis[N-(carboxymethyl)glycinato]](4-)-N,N',O,O',ON,ON']-, ammonium, (OC-6-2Ferrate(1-)

Ethylenediaminetetracetic acid, ferric ammonium salt

Ferrate(1-), [[N,N'-1,2-ethanediylbis[N-(carboxymethyl)glycinato]](4-)-N,N',O,O',ON, ON']-, ammonium； on']-, ammonium, (oc-6-21)-on

ammonium iron(iii) ethylenediaminetetraacetate

Ethlene diamine tetraacetic acid ferric ammonium salt； edta ferric ammonium salt
Ferrate(1-),[[N,N'-1,2-ethanediylbis[N-(carboxymethyl)glycinato]](4-)-

N,N',O,O',ON,ON']-,ammonium,(OC-6-21)-

Ethylenediaminetetracetic acid,ferric ammonium salt

Ferrate(1-),[[N,N'-1,2-ethanediylbis[N-(carboxymethyl)glycinato]](4-)-N,N',O,O',ON,ON']-,ammonium

性状描述：土黄色结晶粉末。无毒，加热至230℃分解。溶于水和酸，微溶于乙醇。

用途：主要用作氧化剂；感光材料冲洗加工漂白剂和减薄剂。

说明：补充资料仅用于学习参考，请勿用于其它任何用途。